Stansberry Asset Management, LLC Cellectis S.A. Transaction History

Stansberry Asset Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$15.58 - $28.41 $1.72 Million - $3.13 Million	-110,245 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$25.99 - $30.6 $149,910 - $176,500	5,768 Added 5.52%	110,245 $3.11 Million
Q2 2018 Aug 14, 2018	BUY	$27.78 - $38.53 $2.9 Million - $4.03 Million	104,477 New	104,477 $2.96 Million

9.73M

30.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $101M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Stansberry Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Stansberry Asset Management, LLC with notifications on news.